Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;16(4):211-221.
doi: 10.34172/jcvtr.33230. Epub 2024 Dec 23.

Post-transplant cyclophosphamide-induced cardiotoxicity: A comprehensive review

Azin Alizadehasl  1 , Bita Shahrami  2   3 , Reza Rahbarghazi  4   5 , Azam Yalameh Aliabadi  1 , Seyedeh Fatemeh Hosseini Jebelli  1 , Yasamin Afsari Zonooz  1 , Hoda Hakimian  1 , Farzaneh Fathi  6 , Sara Forati  1 , Aysa Rezabakhsh  7
Affiliations
Review

Post-transplant cyclophosphamide-induced cardiotoxicity: A comprehensive review

Azin Alizadehasl et al. J Cardiovasc Thorac Res. 2024.

Abstract

Cyclophosphamide-induced cardiotoxicity, associated with its toxic metabolite acrolein, is a significant concern and unresolved issue, especially when cyclophosphamide is administrated in high doses. However, cardiotoxicity following low-dose cyclophosphamide has been also documented, especially in post-hematopoietic stem cell transplantation (post-HSCT) settings. Despite the involvement of multiple signaling pathways in cyclophosphamide-induced cardiomyopathy, the exact underlying mechanisms remain to be fully elucidated. This review outlines the current challenges of cyclophosphamide therapy in HSCT recipients. In addition, the promising therapeutic approaches by targeting acrolein's anti-angiogenic effect were thoroughly discussed to better manage post-HSCT cyclophosphamide-induced cardiotoxicity.

Keywords: Acrolein; Angiogenesis; Cardiotoxicity; Cyclophosphamide; Hematopoietic stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declared that they have no conflict of interest regarding this work.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
See this image and copyright information in PMC

References

    1. Zhang L, Zhou J, Hu L, Han X, Zou X, Chen Q, et al. In situ formed fibrin scaffold with cyclophosphamide to synergize with immune checkpoint blockade for inhibition of cancer recurrence after surgery. Adv Funct Mater. 2020;30(7):1906922. doi: 10.1002/adfm.201906922. - DOI
    1. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11. doi: 10.1016/j.ctrv.2010.11.001. - DOI - PubMed
    1. Podgurskaya AD, Slotvitsky MM, Tsvelaya VA, Frolova SR, Romanova SG, Balashov VA, et al. Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes. Sci Rep. 2021;11(1):2336. doi: 10.1038/s41598-020-79085-5. - DOI - PMC - PubMed
    1. Swan D, Gurney M, Krawczyk J, Ryan AE, O’Dwyer M. Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma. Hemasphere. 2020;4(2):e350. doi: 10.1097/hs9.0000000000000350. - DOI - PMC - PubMed
    1. Quan XY, Chen HT, Liang SQ, Yang C, Yao CW, Xu YZ, et al. Revisited cyclophosphamide in the treatment of lupus nephritis. Biomed Res Int. 2022;2022:8345737. doi: 10.1155/2022/8345737. - DOI - PMC - PubMed

LinkOut - more resources